Cargando…
Circulating HPV cDNA in the blood as a reliable biomarker for cervical cancer: A meta-analysis
The applications of liquid biopsy have attracted much attention in biomedical research in recent years. Circulating cell-free DNA (cfDNA) in the serum may serve as a unique tumor marker in various types of cancer. Circulating tumor DNA (ctDNA) is a type of serum cfDNA found in patients with cancer a...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7004305/ https://www.ncbi.nlm.nih.gov/pubmed/32027658 http://dx.doi.org/10.1371/journal.pone.0224001 |
_version_ | 1783494694635831296 |
---|---|
author | Gu, Yulan Wan, Chuandan Qiu, Jiaming Cui, Yanhong Jiang, Tingwang Zhuang, Zhixiang |
author_facet | Gu, Yulan Wan, Chuandan Qiu, Jiaming Cui, Yanhong Jiang, Tingwang Zhuang, Zhixiang |
author_sort | Gu, Yulan |
collection | PubMed |
description | The applications of liquid biopsy have attracted much attention in biomedical research in recent years. Circulating cell-free DNA (cfDNA) in the serum may serve as a unique tumor marker in various types of cancer. Circulating tumor DNA (ctDNA) is a type of serum cfDNA found in patients with cancer and contains abundant information regarding tumor characteristics, highlighting its potential diagnostic value in the clinical setting. However, the diagnostic value of cfDNA as a biomarker, especially circulating HPV DNA (HPV cDNA) in cervical cancer remains unclear. Here, we performed a meta-analysis to evaluate the applications of HPV cDNA as a biomarker in cervical cancer. A systematic literature search was performed using PubMed, Embase, and WANFANG MED ONLINE databases up to March 18, 2019. All literature was analyzed using Meta Disc 1.4 and STATA 14.0 software. Diagnostic measures of accuracy of HPV cDNA in cervical cancer were pooled and investigated. Fifteen studies comprising 684 patients with cervical cancer met our inclusion criteria and were subjected to analysis. The pooled sensitivity and specificity were 0.27 (95% confidence interval [CI], 0.24–0.30) and 0.94(95% CI, 0.92–0.96), respectively. The pooled positive likelihood ratio and negative likelihood ratio were 6.85 (95% CI, 3.09–15.21) and 0.60 (95% CI, 0.46–0.78), respectively. The diagnostic odds ratio was 15.25 (95% CI, 5.42–42.94), and the area under the summary receiver operating characteristic curve was 0.94 (95% CI, 0.89–0.99). There was no significant publication bias observed. In the included studies, HPV cDNA showed clear diagnostic value for diagnosing and monitoring cervical cancer. Our meta-analysis suggested that detection of HPV cDNA in patients with cervical cancer could be used as a noninvasive early dynamic biomarker of tumors, with high specificity and moderate sensitivity. Further large-scale prospective studies are required to validate the factors that may influence the accuracy of cervical cancer diagnosis and monitoring. |
format | Online Article Text |
id | pubmed-7004305 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | Public Library of Science |
record_format | MEDLINE/PubMed |
spelling | pubmed-70043052020-02-18 Circulating HPV cDNA in the blood as a reliable biomarker for cervical cancer: A meta-analysis Gu, Yulan Wan, Chuandan Qiu, Jiaming Cui, Yanhong Jiang, Tingwang Zhuang, Zhixiang PLoS One Research Article The applications of liquid biopsy have attracted much attention in biomedical research in recent years. Circulating cell-free DNA (cfDNA) in the serum may serve as a unique tumor marker in various types of cancer. Circulating tumor DNA (ctDNA) is a type of serum cfDNA found in patients with cancer and contains abundant information regarding tumor characteristics, highlighting its potential diagnostic value in the clinical setting. However, the diagnostic value of cfDNA as a biomarker, especially circulating HPV DNA (HPV cDNA) in cervical cancer remains unclear. Here, we performed a meta-analysis to evaluate the applications of HPV cDNA as a biomarker in cervical cancer. A systematic literature search was performed using PubMed, Embase, and WANFANG MED ONLINE databases up to March 18, 2019. All literature was analyzed using Meta Disc 1.4 and STATA 14.0 software. Diagnostic measures of accuracy of HPV cDNA in cervical cancer were pooled and investigated. Fifteen studies comprising 684 patients with cervical cancer met our inclusion criteria and were subjected to analysis. The pooled sensitivity and specificity were 0.27 (95% confidence interval [CI], 0.24–0.30) and 0.94(95% CI, 0.92–0.96), respectively. The pooled positive likelihood ratio and negative likelihood ratio were 6.85 (95% CI, 3.09–15.21) and 0.60 (95% CI, 0.46–0.78), respectively. The diagnostic odds ratio was 15.25 (95% CI, 5.42–42.94), and the area under the summary receiver operating characteristic curve was 0.94 (95% CI, 0.89–0.99). There was no significant publication bias observed. In the included studies, HPV cDNA showed clear diagnostic value for diagnosing and monitoring cervical cancer. Our meta-analysis suggested that detection of HPV cDNA in patients with cervical cancer could be used as a noninvasive early dynamic biomarker of tumors, with high specificity and moderate sensitivity. Further large-scale prospective studies are required to validate the factors that may influence the accuracy of cervical cancer diagnosis and monitoring. Public Library of Science 2020-02-06 /pmc/articles/PMC7004305/ /pubmed/32027658 http://dx.doi.org/10.1371/journal.pone.0224001 Text en © 2020 Gu et al http://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/) , which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. |
spellingShingle | Research Article Gu, Yulan Wan, Chuandan Qiu, Jiaming Cui, Yanhong Jiang, Tingwang Zhuang, Zhixiang Circulating HPV cDNA in the blood as a reliable biomarker for cervical cancer: A meta-analysis |
title | Circulating HPV cDNA in the blood as a reliable biomarker for cervical cancer: A meta-analysis |
title_full | Circulating HPV cDNA in the blood as a reliable biomarker for cervical cancer: A meta-analysis |
title_fullStr | Circulating HPV cDNA in the blood as a reliable biomarker for cervical cancer: A meta-analysis |
title_full_unstemmed | Circulating HPV cDNA in the blood as a reliable biomarker for cervical cancer: A meta-analysis |
title_short | Circulating HPV cDNA in the blood as a reliable biomarker for cervical cancer: A meta-analysis |
title_sort | circulating hpv cdna in the blood as a reliable biomarker for cervical cancer: a meta-analysis |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7004305/ https://www.ncbi.nlm.nih.gov/pubmed/32027658 http://dx.doi.org/10.1371/journal.pone.0224001 |
work_keys_str_mv | AT guyulan circulatinghpvcdnainthebloodasareliablebiomarkerforcervicalcancerametaanalysis AT wanchuandan circulatinghpvcdnainthebloodasareliablebiomarkerforcervicalcancerametaanalysis AT qiujiaming circulatinghpvcdnainthebloodasareliablebiomarkerforcervicalcancerametaanalysis AT cuiyanhong circulatinghpvcdnainthebloodasareliablebiomarkerforcervicalcancerametaanalysis AT jiangtingwang circulatinghpvcdnainthebloodasareliablebiomarkerforcervicalcancerametaanalysis AT zhuangzhixiang circulatinghpvcdnainthebloodasareliablebiomarkerforcervicalcancerametaanalysis |